Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
about
Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceResistance to antibiotics targeted to the bacterial cell wallDiscovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative BacteriaPreclinical evaluation of novel antibacterial agents by microbiological and molecular techniquesPervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutationsThe glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosaCharacterization of the indole-3-glycerol phosphate synthase from Pseudomonas aeruginosa PAO1Intra-subtype variation in enteroadhesion accounts for differences in epithelial barrier disruption and is associated with metronidazole resistance in Blastocystis subtype-7Antimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland ChinaFitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.Reversibility of antibiotic resistanceFosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.Mutations of the Transporter Proteins GlpT and UhpT Confer Fosfomycin Resistance in Staphylococcus aureus.Challenges of antibacterial discoveryPrevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes'Old' antibiotics for emerging multidrug-resistant bacteriaReducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes.Glutathione transferases in bacteria.Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in TaiwanGenomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness costCarbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsMolecular Basis for Resistance Against Phosphonate Antibiotics and Herbicides.In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillinFosfomycinOptimizing drug exposure to minimize selection of antibiotic resistance.Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains.Determinants of Genetic Diversity of Spontaneous Drug Resistance in BacteriaFosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.Structural basis of substrate selectivity in the glycerol-3-phosphate: phosphate antiporter GlpT.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.Viable screening targets related to the bacterial cell wall.Confronting carbapenemase-producing Klebsiella pneumoniae.Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.
P2860
Q26853135-E1338294-BBC3-4009-ABB0-87C1D19BC151Q26859841-EBFD2459-FF7C-45C3-9019-0CDB788EAD82Q27675792-96156B07-F2BA-4F72-BA0D-BF1ED52346A6Q28273315-55C9421C-6631-45EE-8BE2-73B672438B90Q28476356-861AA691-C3C6-410A-A266-3721F6E9FFC5Q28492495-C87202C0-3733-4DE7-8A5C-767259AE5524Q28492528-383E6490-855E-4F4E-AC0B-8C13B0835803Q28539056-493C93C2-DB37-4345-8CE3-122D816163E6Q28547100-5A4652BA-2B9F-4683-8559-8EC79FEEFDD4Q33264145-F15CD44E-21D1-49A7-BE25-73F721DFEDBBQ33558996-E1362182-0008-4FE4-84DE-14B1E9D29065Q33564290-D25776D3-D49D-4227-B74F-15473C8C8738Q33667524-0A056422-9AC6-4B36-824C-1782887DB90FQ33703401-B7306F01-866D-4C04-B1E6-BE370C099F0BQ33707109-779221AB-FBA4-49AB-8AF2-4F7E833F5CB7Q33793074-84ADE186-CCDC-4805-8A01-A676D6B3EEE3Q33962732-C94C8609-0115-4990-A109-D3914B212EE7Q34565772-8EF3C512-A8C4-45A2-A3F2-17E6D06BA37EQ34598420-5040C7BC-6517-487D-9A86-77F870C9E7F4Q34882983-80152A96-356B-4C1D-B10B-7BF1AF8586EFQ34921154-B94C9307-566B-43E9-A4E7-A10ACC225BDAQ35747796-D6E4DD03-67C5-4830-A127-D4306D17607DQ35941216-B82ACD21-C3AD-47FF-9F72-CEEA0408A679Q36361921-DD702713-B6EC-4711-847B-D87F18657383Q36490822-2004B090-C569-477A-BC2F-F3B930CCE627Q36540547-36E245B8-EDBE-42C7-B9C5-D36ECAE8F0F2Q36669182-43A8D6FE-44F3-4931-B492-8477092AAE10Q36675246-ADC01CF2-7F57-4928-8C90-6A939CDA1848Q36903693-569F6C47-9ACA-43E2-9E5A-C94562132AC0Q37001229-AC1D092A-31C6-432B-A429-8295DBABA2A6Q37076747-696B7005-560D-40AC-9E6E-5DFA8F1A7949Q37263313-CD9C8A65-A342-4EF5-BDD8-CBD247B963D1Q37359448-C1840CBB-4FE0-4151-9076-A821F272AD10Q37377897-4FB42293-ABA2-4E7E-B653-7974D477C38AQ37894694-0702EA55-9178-473A-9855-2CCD405069B3Q37957839-9D62EE69-D02C-4042-9721-43E63CCCCDA5Q38068604-2AFCCF39-79F1-4BA9-8E0D-F0D1A8CBC66CQ38070780-DE0D4701-D33C-4125-8AFE-CA9A4A89FCE5Q38135903-2E8E2094-98A7-4F1E-8EF4-A08C7AF91257Q38160759-8C3B09A4-B387-444B-AFBB-29FF561048C8
P2860
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@ast
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@en
type
label
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@ast
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@en
prefLabel
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@ast
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@en
P2093
P2860
P1476
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.
@en
P2093
Annika I Nilsson
Dan I Andersson
Gunnar Kahlmeter
Olle Aspevall
Otto G Berg
P2860
P304
P356
10.1128/AAC.47.9.2850-2858.2003
P407
P577
2003-09-01T00:00:00Z